Real-world experience with secukinumab in the entire axial spondyloarthritis spectrum

• Published in: Frontiers in medicine 2023-05, Vol.10, p.1156557
• Main Authors: Sivera, Francisca, Núñez-Monje, Victoria, Campos-Fernández, Cristina, Balaguer-Trull, Isabel, Robustillo-Villarino, Montserrat, Aguilar-Zamora, Marta, Garijo-Bufort, Marta, López-Gómez, Juan Miguel, Peña-González, Carolina, de la Morena, Isabel, Bedoya-Sanchís, Diego, Yankova-Komsalova, Liliya, Conesa-Mateos, Arantxa, Martínez-Cristóbal, Anna, Navarro-Blasco, Francisco Javier, Senabre-Gallego, José Miguel, Alegre-Sancho, Juan José
• Format: Article
• Language: English
• Subjects: ankylosing spondylitis; axial spondyloarthritis; effectiveness; Medicine; non-radiographic axial spondyloarthritis; real-world evidence; secukinumab
• ISSN: 2296-858X; 2296-858X
• DOI: 10.3389/fmed.2023.1156557

Secukinumab is a biologic disease-modifying antirheumatic drug (bDMARD) that has demonstrated efficacy in the treatment of axial spondyloarthritis (axSpA, i.e., ankylosing spondylitis and non-radiographic axSpA) across various clinical trials. However, data of secukinumab in clinical practice is still limited. Here, we aimed to provide real-world data on secukinumab use, effectiveness, and persistence in axSpA. Retrospective, multicenter study of patients with a diagnosis of axSpA treated with secukinumab at 12 centers up to June 2021 in the Valencian Community (Spain). Information was gathered on BASDAI measurement, pain, patient and physician global assessment (ptGA, phGA) using a 100-mm visual analog scale (VAS), persistence and other secondary variables by treatment line (first, second, and ≥ third) for up to 24 months. 221 patients were included (69% men; mean age [standard deviation, SD]: 46.7 [12.1] years old). Secukinumab was used as a first-line bDMARD in 38% of patients, as a second-line in 34% and as a ≥ hird-line in 28%. The percentage of patients achieving low disease activity (BASDAI